Work

Formulation, Optimization and Characterization of Preliminary Screening of Materials Iguratimod Loaded NLCs

Year: 2024

Type: article

Abstract: Rheumatoid arthritis is treated with iguratimod. Disease-modifying anti-rheumatic medication iguratimod. Rheumatoid arthritis inflammation is reduced by improving aberrant immune response and decreasing inflammation-causing chemicals. This paper optimised Iguratimod-loaded NLC formulation using Box Behnken design. 13 randomised runs were produced for the experiment. This paper examined how independent variable levels affected response variables.

Source: International Journal of Pharmaceutical Quality Assurance

DOI: 10.25258/ijpqa.15.4.66

Authors: Ahire Sujeetkumar Ishwarlal, Gupta Revathi A

Language: English

Topic: Advancements in Transdermal Drug Delivery

Subfield: Pharmaceutical Science

Field: Pharmacology, Toxicology and Pharmaceutics

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4410903191

FWCI:

Cites:

Cited by:

Related to: 10